Raymond James & Associates’s Elevance Health ELV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $141M | Buy |
271,927
+3,366
| +1% | +$1.8M | 0.09% | 201 |
|
|
2024
Q2 | $146M | Buy |
268,561
+4,756
| +2% | +$2.51M | 0.1% | 182 |
|
|
2024
Q1 | $137M | Buy |
263,805
+14,161
| +6% | +$7.04M | 0.09% | 195 |
|
|
2023
Q4 | $118M | Buy |
249,644
+6,081
| +2% | +$2.81M | 0.09% | 203 |
|
|
2023
Q3 | $106M | Buy |
243,563
+65,719
| +37% | +$29.8M | 0.09% | 198 |
|
|
2023
Q2 | $79M | Sell |
177,844
-16,768
| -9% | -$7.74M | 0.07% | 258 |
|
|
2023
Q1 | $89.5M | Buy |
194,612
+32,569
| +20% | +$15.5M | 0.08% | 227 |
|
|
2022
Q4 | $83.1M | Buy |
162,043
+12,217
| +8% | +$6.2M | 0.08% | 239 |
|
|
2022
Q3 | $68.1M | Sell |
149,826
-6,635
| -4% | -$3.17M | 0.07% | 251 |
|
|
2022
Q2 | $75.5M | Sell |
156,461
-1,798
| -1% | -$889K | 0.07% | 239 |
|
|
2022
Q1 | $77.7M | Buy |
158,259
+12,327
| +8% | +$5.63M | 0.07% | 256 |
|
|
2021
Q4 | $67.6M | Buy |
145,932
+10,584
| +8% | +$4.45M | 0.05% | 290 |
|
|
2021
Q3 | $50.5M | Buy |
135,348
+6,950
| +5% | +$2.64M | 0.05% | 352 |
|
|
2021
Q2 | $49M | Buy |
128,398
+21,098
| +20% | +$8.06M | 0.04% | 354 |
|
|
2021
Q1 | $38.5M | Sell |
107,300
-2,536
| -2% | -$816K | 0.04% | 399 |
|
|
2020
Q4 | $35.3M | Buy |
109,836
+72
| +0.1% | +$22.1K | 0.04% | 403 |
|
|
2020
Q3 | $29.5M | Sell |
109,764
-1,470
| -1% | -$396K | 0.04% | 404 |
|
|
2020
Q2 | $29.3M | Buy |
111,234
+5,345
| +5% | +$1.43M | 0.04% | 381 |
|
|
2020
Q1 | $24M | Buy |
105,889
+3,118
| +3% | +$850K | 0.04% | 390 |
|
|
2019
Q4 | $31M | Sell |
102,771
-2,035
| -2% | -$560K | 0.04% | 395 |
|
|
2019
Q3 | $25.2M | Sell |
104,806
-2,999
| -3% | -$822K | 0.04% | 460 |
|
|
2019
Q2 | $30.4M | Buy |
107,805
+16,233
| +18% | +$4.43M | 0.04% | 399 |
|
|
2019
Q1 | $26.3M | Sell |
91,572
-26,391
| -22% | -$7.63M | 0.04% | 430 |
|
|
2018
Q4 | $31M | Buy |
117,963
+26,054
| +28% | +$7.16M | 0.05% | 319 |
|
|
2018
Q3 | $25.2M | Buy |
91,909
+7,397
| +9% | +$1.92M | 0.04% | 448 |
|
|
2018
Q2 | $20.1M | Buy |
84,512
+15,129
| +22% | +$3.5M | 0.03% | 504 |
|
|
2018
Q1 | $15.2M | Sell |
69,383
-10,907
| -14% | -$2.56M | 0.03% | 571 |
|
|
2017
Q4 | $18.1M | Sell |
80,290
-2,419
| -3% | -$515K | 0.03% | 512 |
|
|
2017
Q3 | $15.7M | Sell |
82,709
-7,543
| -8% | -$1.44M | 0.03% | 542 |
|
|
2017
Q2 | $17M | Buy |
90,252
+20,213
| +29% | +$3.63M | 0.04% | 490 |
|
|
2017
Q1 | $11.6M | Buy |
70,039
+20,153
| +40% | +$3.21M | 0.03% | 592 |
|
|
2016
Q4 | $7.17M | Buy |
49,886
+13,109
| +36% | +$1.76M | 0.02% | 804 |
|
|
2016
Q3 | $4.61M | Sell |
36,777
-16,924
| -32% | -$2.19M | 0.01% | 991 |
|
|
2016
Q2 | $7.05M | Sell |
53,701
-18,232
| -25% | -$2.49M | 0.02% | 686 |
|
|
2016
Q1 | $10M | Buy |
71,933
+1,192
| +2% | +$159K | 0.03% | 521 |
|
|
2015
Q4 | $9.86M | Buy |
70,741
+11,269
| +19% | +$1.55M | 0.04% | 525 |
|
|
2015
Q3 | $8.33M | Sell |
59,472
-2,794
| -4% | -$420K | 0.03% | 553 |
|
|
2015
Q2 | $10.2M | Buy |
62,266
+9,644
| +18% | +$1.54M | 0.04% | 517 |
|
|
2015
Q1 | $8.13M | Buy |
52,622
+23,271
| +79% | +$3.31M | 0.04% | 532 |
|
|
2014
Q4 | $3.69M | Buy |
29,351
+13,179
| +81% | +$1.63M | 0.02% | 831 |
|
|
2014
Q3 | $1.93M | Buy |
16,172
+1,158
| +8% | +$133K | 0.01% | 1117 |
|
|
2014
Q2 | $1.62M | Buy |
15,014
+2,556
| +21% | +$263K | 0.01% | 1213 |
|
|
2014
Q1 | $1.24M | Buy |
+12,458
| New | +$1.13M | 0.01% | 1302 |
|
|
2013
Q3 | – | Sell |
-18,388
| Closed | -$1.5M | – | 1920 |
|
|
2013
Q2 | $1.5M | Buy |
+18,388
| New | +$1.38M | 0.01% | 955 |
|
Other funds holding ELV
Raymond James & Associates's ELV Position: Q3 2024 in Review
Raymond James & Associates increased its Elevance Health (ELV) stake by 1.3% in Q3 2024, buying an estimated $1.8M and bringing the position to 271,927 shares worth $141M. The position accounts for 0.09% of the portfolio, ranked #201.
Raymond James & Associates first reported a position in ELV in Q2 2013 and has held it in 44 quarters since. The position peaked at $146M in Q2 2024. 1,694 funds tracked by Wall St. Rank hold ELV as of Q3 2024.
- Raymond James & Associates held 271,927 shares of Elevance Health worth $141M as of Q3 2024.
- Raymond James & Associates bought 3,366 Elevance Health shares in Q3 2024, an estimated $1.8M.
- Elevance Health made up 0.09% of Raymond James & Associates's portfolio in Q3 2024, its #201 holding.
- Raymond James & Associates first reported a position in Elevance Health in Q2 2013 and has held it in 44 quarters since.
- Raymond James & Associates's Elevance Health position peaked at $146M in Q2 2024.
- 1,694 funds tracked by Wall St. Rank held Elevance Health as of Q3 2024.
Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.